PR Newswire | Jun 16, 2021 08:02AM EDT

06/16 07:00 CDT

GT Biopharma to Present at Raymond James Human Health Innovation Conference BEVERLY HILLS, Calif., June 16, 2021

BEVERLY HILLS, Calif., June 16, 2021 /PRNewswire/ --GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE(tm)) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

A live webcast of the event will be available by visiting "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations. A replay of the webcast will be archived for 30 days following the presentation.

About GT Biopharma, Inc.GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE(tm) NK cell engager platform. Our TriKE(tm) platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE(tm) technology. For more information, please visit gtbiopharma.com.

Investor Contact: Investor and Media Relations Contact:

Brendan Payne David Castaneda

Client Lead David@gtbiopharma.com

Stern Investor Relations, Inc. 414-351-9758

brendan.payne@sternir.com

212-362-1200

View original content: http://www.prnewswire.com/news-releases/gt-biopharma-to-present-at-raymond-james-human-health-innovation-conference-301313508.html

SOURCE GT Biopharma, Inc.